Send to

Choose Destination
Gynecol Oncol. 2017 Apr;145(1):148-153. doi: 10.1016/j.ygyno.2017.02.006. Epub 2017 Feb 12.

Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.

Author information

Department of Otolaryngology, Head and Neck Surgery, Rikshospitalet, Oslo University Hospital, Norway.
Department of Gynecological Oncology, Radiumhospitalet, Oslo University Hospital, Norway.
National Resource Center for Late Effects after Cancer Treatment, Radiumhospitalet, Oslo University Hospital, Norway. Electronic address:
Department of Health Science and Biostatistics, Høgskolen i Oslo og Akershus, Norway.
Department of Clinical Pharmacology, St Olav University Hospital, Trondheim, Norway.



Evaluate long-term cisplatin-induced ototoxicity in women treated for malignant ovarian germ cell tumors (MOGCT).


Seventy-four women treated for MOGCT in Norway (1980-2009) were analyzed: 41 had received cisplatin-based chemotherapy (CBCT) ("Cases") and 33 had no CBCT ("Controls"). Median follow-up was 15years. Hearing was assessed by pure tone audiometry and by the SCIN questionnaire. Air conduction thresholds were reported as absolute hearing thresholds and age-adjusted thresholds. Absolute and age-adjusted hearing loss were defined as thresholds of >20dB at any frequency. Tinnitus was evaluated using the Tinnitus Handicap Inventory. Serum Platinum Concentration (SPC) was determined.


Absolute hearing loss was identified in 21 Cases (51%) and 24 Controls (73%). After adjusting for age, only 9 Cases (22%) and 5 Controls (15%) remained. Age-adjusted hearing thresholds at 4, 6 and 8kHz were slightly but significantly higher in Cases compared to Controls. Subjective hearing loss was reported by 27% of Cases and 21% of Controls, who were significantly older. Elevated SPC values were detected up to 20years after CBCT, but SPC did not correlate significantly with age-adjusted hearing loss. The rate of tinnitus was similar in Cases and Controls.


Long-term MOGCT survivors treated with CBCT have small but significant reductions in age-adjusted hearing thresholds at 4, 6 and 8kHz versus Controls. Approximately one in four women experienced subjective hearing loss. To avoid overestimation of clinically relevant cisplatin-induced ototoxicity, absolute hearing thresholds should be age-adjusted and compared to an age-matched control group.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center